Tag: Novo Nordisk

Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 – a cell therapy designed to restore heart function in people with advanced heart failure

Coronary/Structural Heart by 0 comments

HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs). Clinical phase 1/2 study (LAPiS Study) will enrol 10 patients with advanced heart failure caused by ischaemic heart disease. Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in […]

Continue Reading →

World’s largest study of cardiovascular disease in type 2 diabetes shows need for improved knowledge and disease management

Coronary/Structural Heart by 0 comments

Bagsværd, Denmark, 24 September 2020 – Novo Nordisk today announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first of its kind and involving nearly 10,000 participants […]

Continue Reading →

ACC, Novo Nordisk Partner to Improve Cardiovascular Disease Management in Patients with Type 2 Diabetes

Financial by 0 comments

New initiative will identify gaps in care, spur quality improvement in treating vulnerable patients WASHINGTON, Sept. 10, 2020 /PRNewswire/ — The American College of Cardiology, in partnership with Novo Nordisk Inc., is launching Transforming Cardiovascular Risk in Diabetes (TRANSFORM CVRiD), a new, two-year health care quality initiative to promote cardiovascular risk reduction and […]

Continue Reading →
1 2